DIVERSITY OF CD4(+) BLOOD T-CELL CLONALITY PREDICTS LONGER SURVIVAL WITH CTLA4 OR PD-1 CHECKPOINT INHIBITION IN ADVANCED MELANOMA
Arakawa A, Vollmer S, Tietze J, Galinski A, Heppt M, Berking C, Prinz JC (2021)
Publication Language: English
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: BMJ PUBLISHING GROUP
City/Town: LONDON
Pages Range: A17-A17
Conference Proceedings Title: JOURNAL FOR IMMUNOTHERAPY OF CANCER
DOI: 10.1136/jitc-2021-ITOC8.31
Authors with CRIS profile
Markus Heppt
Department of Dermatology
Carola Berking
Lehrstuhl für Haut- und Geschlechtskrankheiten
Involved external institutions
Germany (DE)How to cite
APA:
Arakawa, A., Vollmer, S., Tietze, J., Galinski, A., Heppt, M., Berking, C., & Prinz, J.C. (2021). DIVERSITY OF CD4(+) BLOOD T-CELL CLONALITY PREDICTS LONGER SURVIVAL WITH CTLA4 OR PD-1 CHECKPOINT INHIBITION IN ADVANCED MELANOMA. In JOURNAL FOR IMMUNOTHERAPY OF CANCER (pp. A17-A17). LONDON: BMJ PUBLISHING GROUP.
MLA:
Arakawa, A., et al. "DIVERSITY OF CD4(+) BLOOD T-CELL CLONALITY PREDICTS LONGER SURVIVAL WITH CTLA4 OR PD-1 CHECKPOINT INHIBITION IN ADVANCED MELANOMA." Proceedings of the JOURNAL FOR IMMUNOTHERAPY OF CANCER LONDON: BMJ PUBLISHING GROUP, 2021. A17-A17.
BibTeX: Download